Evidence map›Paper›PMID 38592002›Full record

Observational studyFuture oncology (London, England)2024

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.

Valentina Guarneri, José Luís Passos Coelho, Francois P Duhoux, Daniel Egle, José Ángel García-Sáenz, Frédérique Penault-Llorca, Katri Selander, Hans Wildiers, Khalil Zaman, Petra Laeis and 2 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05945732 (A Prospective, Non-interventional Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05945732 recruitingnot on this map

A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)

TypeobservationalSponsorDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRan2023 to 2030Enrolled2,295ConditionsUnresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast CancerArmsTrastuzumab deruxtecan
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Valentina GuarneriMedical Oncology 2, Veneto Institute of Oncology (IOV), IRCCS, Via Gattamelata, 64, 35128 Padova PD, Italy.
José Luís Passos CoelhoOncology Department, Hospital da Luz, Av. Lusίada 100, 1500-650 Lisbon, Portugal.
Francois P DuhouxDepartment of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Av. Hippocrate 10, 1200 Brussels, Belgium.
Daniel EgleDepartment of Gynaecology & Obstetrics, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, Fritz-Pregl-Straße 3, 6020 Innsbruck, Austria.
José Ángel García-SáenzDepartment of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Calle del Prof Martin Lagos, s/n, Moncloa - Aravaca, 28040 Madrid, Spain.ORCID 0000-0001-6880-0301
Frédérique Penault-LlorcaCentre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire Et Stratégies Théranostiques, Rue Montalebert, 63000 Clermont-Ferrand, France.
Katri SelanderDepartment of Oncology & Radiation Therapy, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland.
Hans WildiersDepartment of General Medical Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Khalil ZamanDepartment of Oncology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Petra LaeisDaiichi Sankyo Europe GmbH, Zielstattstraße 48 81379 Munich, Germany.
Markus LucernaDaiichi Sankyo Europe GmbH, Zielstattstraße 48 81379 Munich, Germany.
Jean-Yves PiergaDepartment of Medical Oncology, Institut Curie, Université Paris Cité, 75005 Paris, France.

Funding

Daiichi Sankyo Europe
6 · The paper itself

Abstract

Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd treatment in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond HER2-low Europe (NCT05945732) is a multi-center, multi-country, observational, prospective, non-interventional study planning to enroll 1350 patients from 216 sites receiving T-DXd or conventional chemotherapy as their routine clinical care for advanced stage breast cancer in 12 European countries. This non-interventional study will provide real-world insight into T-DXd treatment for HER2-low mBC with data on effectiveness, safety and tolerability, patient-reported outcomes, treatment patterns, geriatric health status and HER2 testing. This will be beneficial for improving guidance to maximize patient treatment benefit.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsCamptothecinEuropeFemaleHumansImmunoconjugatesNeoplasm StagingProspective StudiesResearch DesignTreatment OutcomeCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecanadverse eventsHER2-lowmetastatic breast canceroverall survivalpatient-reported outcomesprogression-free survivaltrastuzumab deruxtecan

Identifiers

PMID38592002
PMCPMC11318675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.